AHR

The aryl hydrocarbon receptor sits quietly in the cell's fluid until it binds certain flat, ring-shaped chemicals, after which it moves into the nucleus and turns on target genes. Among the genes it activates are enzymes that help the body process foreign chemicals, such as members of the cytochrome P450 family. AHR is located on chromosome 7. The gene also goes by alternate names, including RP85 and FVH3, which reflect proposed links to retinitis pigmentosa and to foveal hypoplasia. These names should be read as candidate associations, because only a small number of reports connect AHR to any inherited retinal condition.

The clearest human link is to foveal hypoplasia, in which the fovea — the tiny central pit of the retina responsible for sharp, detailed central vision — does not fully develop. In a large multicenter study of 907 people with foveal hypoplasia, AHR variants were found only very rarely compared with more common causes such as albinism. The same study suggested that when AHR is involved, the arrest in foveal development tends to occur relatively early. Beyond foveal hypoplasia, direct human evidence tying AHR to conditions such as retinitis pigmentosa is scarce and remains at the hypothesis stage. Because the reports are so few, it is not possible to describe a typical age of onset, severity, or pattern of progression for AHR-related vision changes.

The strongest established fact is molecular, not clinical: AHR is a ligand-activated transcription factor that regulates the body's response to certain aromatic chemicals. In humans, the best-documented retinal finding is that AHR variants can rarely underlie foveal hypoplasia. Laboratory and animal work points to a protective role for AHR in the retina. In mice engineered to lack AHR, the retina showed inflammation, activation of immune cells called microglia, and early degeneration on the electroretinogram (definition: A test (often abbreviated ERG) that measures the retina's electrical response to light, used to check how well photoreceptors are working.), a test of retinal electrical activity. In cultured cells and in mice, a synthetic AHR-activating compound called 2AI protected retinal pigment epithelium cells and shielded the retina from light-induced damage. The same compound reduced inflammatory signaling in microglia in laboratory experiments. Related laboratory work has also explored AHR-activating tryptophan byproducts as anti-inflammatory, protective signals in models of retinal injury.

Whether AHR is a genuine cause of retinitis pigmentosa in people is not established, and its listing under the name RP85 rests on very limited evidence. One laboratory study proposed that AHR could be linked to abnormal blood-vessel growth in retinitis pigmentosa, but the authors themselves framed this as a hypothesis requiring confirmation in patients. It is also unknown whether the protective effects seen in mice and cultured cells apply to the human retina. AHR is not covered in GeneReviews, and the total number of retinal reports is small, so its overall role in inherited retinal disease remains an open question.

No therapy targeting AHR has been approved for retinal disease. Research on AHR in the retina is at an early, mostly preclinical (definition: Research done in cells or animals, before a treatment is considered ready to be studied in people.) stage, focused on whether activating AHR can reduce inflammation and protect retinal cells. These are laboratory and animal findings, not treatments available to patients, and much more work would be needed before any such approach could be tested in people.

• Loss of AHR causes retinal inflammation in mice

  Animal and laboratory research

  What was found:

  AHR deficiency drove pro-inflammatory changes, immune cell activation, and early degeneration on electroretinogram testing.

  Why it matters:

  It supports the idea that AHR normally helps protect and maintain the retina.

  Limitation: Findings in mice and cells may not translate to human disease.

• A synthetic AHR activator protects the retina from stress

  Laboratory and animal research

  What was found:

  2AI protected the cells from oxidative injury and reduced light-induced retinal damage in mice.

  Why it matters:

  It illustrates why researchers are interested in AHR as a potential protective target.

  Limitation: This is early preclinical work, not a treatment shown to help people.

• AHR activation calms retinal immune cells

  Laboratory research

  What was found:

  2AI reduced inflammatory signaling and antioxidant stress responses in activated microglia.

  Why it matters:

  It adds mechanistic detail to how AHR may protect the retina through immune regulation.

  Limitation: Cell-based results do not establish benefit in humans.

• A proposed link between AHR and retinitis pigmentosa

  Laboratory research and hypothesis

  What was found:

  The authors flagged AHR (and ROM1) as RP-associated genes that might raise the risk of new blood-vessel formation, and called for genetic confirmation in patients.

  Why it matters:

  It is one of the few reports underlying the RP85 designation, but it is a hypothesis, not proof.

  Limitation: No patient genetic data confirmed the proposed AHR–RP link.

• AHR variants as a rare cause of foveal hypoplasia

  Observational human study

  What was found:

  Most cases were caused by albinism and other genes; AHR variants were identified only very rarely, and the data suggested foveal development is arrested relatively early when AHR is involved.

  Why it matters:

  This is the clearest human evidence linking AHR to a retinal condition and helps explain the alias FVH3.

  Limitation: AHR accounted for only a tiny fraction of cases, so conclusions about AHR specifically rest on very few individuals.

When AHR is linked to foveal hypoplasia, this is a developmental difference in the central retina that is present from early life and mainly affects sharp central vision. For a child, that can mean central vision is a consideration in early visual development and learning, which may be useful to discuss with an eye specialist. Aside from this, the general guidance shown on every gene page applies here.

• How was my AHR variant classified in the laboratory report, and how certain is that classification?
• Do my retinal images or scans show foveal hypoplasia or other specific changes?
• Given that AHR is a candidate gene with limited evidence, could another gene better explain my findings?
• Would additional testing, or testing of relatives, help clarify the diagnosis?
• What kind of monitoring do you recommend for my vision over time?
• Are there any research studies that might be relevant to my situation?

If a genetic report has identified an AHR variant, a helpful next step is to confirm with your care team how that variant was classified — for example, as disease-causing, likely disease-causing, or of uncertain significance. Because AHR is a candidate gene with limited evidence, it can be worth asking whether the finding fully explains your retinal picture or whether another gene should be considered. Genetic counseling can help put a candidate-gene result in context for you and your family.